BioSniper
Phase 1 Start~month

Phase 1 Start: A Phase I, Open-label Study to Assess the Absorption, Distribution, Metabolism, and Excretion (ADME)

June 30, 2026
Company
ASTRAZENECA PLC (AZN)
Indication
Advanced Solid Malignancies

Other upcoming events for AZN

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Inves
Jun 19, 2026
Phase 3 ReadoutPhase 3 Topline: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulves
Jun 22, 2026
Phase 1 StartPhase 1 Start: A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokin
Jun 24, 2026
Phase 3 ReadoutPhase 3 Topline: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of C
Jun 30, 2026
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety
Jun 30, 2026

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
AZN OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle